Background: CA 125 assays enable treatment response monitoring in ovarian cancer. Patients and methods: This multicentric study was carried out to assess the prognostic value of the CA 125 change after the first and the second courses of induction chemotherapy (CT). Of the 494 stage IIc-IV patients, 194 had a surgical second look, 397 (80.4%) relapsed and 382 (77.3%) died from cancer. Median (range) follow-up time was 34 months (3-215 months).
introduction
The prognosis of advanced ovarian cancers remains very poor, due to tumour extent at the time of diagnosis and to the limited efficacy of treatment of advanced stages [1] . It would be extremely valuable for optimising therapeutic management to identify early indicators of the response to chemotherapy (CT). As CA 125 levels are easy to determine and elevated in 90% of cases, we studied their value at different time points during the first courses of induction CT as a surrogate marker for patient responsiveness. We recently showed that the rate of CA 125 levels decreases during CT and its initial half-life can be extremely helpful to clinicians [2] . This approach, however, requires a dedicated software, so we sought for other criteria, easier to determine and directly usable by the clinician in routine clinical practice. In this retrospective multicentric study of stage IIc-IV patients, we evaluated the prognostic value of changes in CA 125 levels after one or two CT cycles for overall survival (OS). In addition, we evaluated the predictive value of these CA 125 variations with regard to pathological complete response (pCR) at second-look laparotomy (SLL) in patients showing clinical complete response (cCR) after treatment completion.
patients and methods patient selection
Four hundred and ninety-four patients with epithelial ovarian cancer diagnosed and treated in eight French Cancer Centres were retrospectively studied. Their primary treatment was carried out from 1988 to 1996 and the study end point was May 2005 [2] . Diagnostic and treatment procedures, identical in each Centre, followed standard methods described in the Standards Options et Recommendations of the French Fédération des Centres de Lutte Contre le Cancer [1] . Patient characteristics are summarised in Table 1 . All patients underwent a primary laparotomy and received a first line of CT with platinum salts and cyclophosphamide. To ensure treatment homogeneity, patients treated by taxanes were excluded from our study.
Tumour stage and histological diagnosis were determined according to the criteria of the International Federation of Gynaecology and Obstetrics (FIGO) and the histological typing system of the World Health Organisation, respectively. Tumour grading was not included in the analyses due to insufficient reproducibility [1] . Induction CT started 2-4 weeks after surgery and patients received six courses of CT. Treatment evaluation was on the basis of biological and clinical data recorded at each cycle and on medical imaging. During and after CT, chest X-rays, abdominopelvic scans, magnetic resonance imaging or ultrasonography were carried out according to identified targets. Three to five weeks after the end of CT, a SLL was carried out in 194 stage III patients with cCR. A pCR was defined as the disappearance of all tumour deposits with negative peritoneal washing and negative multiple random biopsies.
CA 125 determination
All patients had a CA 125 determination before each cycle of CT (on average each 3 weeks). Depending on the Centre, three different assay formats were used for CA 125 determination [2] . All the assays were on the basis of the use of Centocor/FujirebioÒ antibodies. IRMA-mat CA 125 II technique (DiaSorin, Antony, France) was used in the Bordeaux Centre for 77 patients, CPE CA 125 II kit (CIS Bio International, Gif-sur-Yvette, France) was used for 130 patients from the Dijon and Toulouse Centres and ELSA CA 125 II technique (CIS Bio International, Gif-sur-Yvette, France) was used for 223 patients monitored in the Nantes, Rouen, Reims, Saint-Cloud and Angers Centres. Each Centre consistently used the same technique during patient monitoring. All determinations were carried out in duplicate and the threshold for CA 125 elevation was 35 kU/l for all methods, as indicated by the manufacturer.
analysis of early changes in CA 125 levels Different biological variables derived from CA 125 kinetics during the first two CT courses were examined: (i) the relative change in CA 125 levels from baseline CA 125 (before the first CT course) to CA 125 before the second CT course (denoted C1.2-CA 125); (ii) the relative change in CA 125 levels from baseline CA 125 to CA 125 before the third CT cycle (denoted C1.3-CA 125); (iii) the relative change in CA 125 concentration before the second to the third CT cycles (denoted C2.3-CA 125) and (iv) CA 125 measured before the third CT cycle. All changes in CA 125 levels were expressed as a percentage of its baseline value. To ensure unbiased calculations of CA 125 changes, only variations relying on a baseline CA 125 concentration >35 kU/l were calculated (the cases with initial CA 125 £35 kU/l were considered as nonassessable). Since treatment was given in 21-day cycles, the time points before the second and third cycles are equivalent to 3-and 6-weeks post-CT initiation.
Changes in CA 125 levels (C1.2-CA 125, C1.3-CA 125 or C2.3-CA 125) were classified in six groups: group 1 = baseline CA 125 £35 kU/l, group 2 = elevated baseline CA 125 increasing during following courses, group 3 = elevated baseline CA 125 and further CA 125 decreasing by ‡75% during treatment, group 4 = elevated baseline CA 125 and CA 125 decreasing by 50%-74% during treatment, group 5 = elevated baseline CA 125 and further CA 125 decrease by 25%-49% and group 6 = elevated baseline CA 125 and CA 125 decrease of <25% (Table 2 ). For CA 125 before the third CT course, patient population was divided in two groups: CA 125 £35 kU/l versus CA 125 >35 kU/l.
statistical methods
Analyses were carried out with STATA version 8. As the biological variables were not normally distributed, we used nonparametric tests (MannWhitney and Kruskall-Wallis tests) and signed quantitative variables were described by median and range (minimum-maximum The prognostic impact of the various relative changes in CA 125 concentration on survival is shown in Table 3 . Noteworthy, the CA 125 concentration measured before the third CT course was found to bear a prognostic value for OS: median OS was 1.9 years (1.6-2.1 years) for patients with a CA 125 >35 kU/l and 4.9 years (4.0-5.4 years) for patients with a CA 125 £35 kU/l [hazard ratio (HR) = 2.7 (2.2-3.3); log-rank test P < 0.0001]. Univariate survival analyses revealed that change in CA 125 levels during the first, second and the two first CT courses, CA 125 before third CT cycle, age, FIGO stage and residual tumour mass all had a strong prognostic value for OS (all with P < 0.0001) ( Table 4 ).
In multivariate analyses including all these factors, change in CA 125 level during the first CT course (P < 0.0001), residual tumour mass (P = 0.003), CA 125 before second CT course (P = 0.037) were found to be independent prognostic variables for OS (Table 4) .
delimiting groups with favourable or poor prognosis
CA 125 kinetics during first CT cycle allowed the identification of two groups with different prognoses. The first group, with a favourable prognosis, included 132 patients: 64 patients with normal CA 125 before each of the two first CT courses and 68 patients with an elevated baseline CA 125 which decreased by >50% during the first CT course and was normalized before the second CT course. The second group had a much poorer prognosis and included 362 patients who did not satisfy all of these criteria. Median OS of patients with favourable prognosis was 6.4 years (4.7-11.2 years). The patients with a poor prognosis had a significantly lower OS [median 2.3 years (1.9-2.6 years)] [HR 2.61 (2.07-3.31); log-rank test P < 0.0001] (Figure 1 ).
Among the 194 stage III patients who underwent a SLL, the frequency of pCR was 77.2% (61 of 79) in the subgroup with favourable prognosis and was only 43.5% (50 of 115) for patients with poor prognosis. This difference was highly significant (v 2 test: P £ 0.0001). Univariate logistic regression analysis identified early changes in CA 125 concentration, residual tumour mass, tumour histology and age as important predictive factors of pCR (P < 0.0001). The multivariate analyses revealed that early change in CA 125 concentration was the most powerful independent predictive factor (P = 0.001) to obtain a pCR at the end of induction CT (Table 5) .
discussion
In the present work, the study population was homogeneous, a particularly important feature for this type of disease, with a long inclusion and follow-up period. Our main result is that CA 125 normalisation induced by the first CT course was an independent prognostic factor both for the probability of achieving a pCR after CT and for OS. The group of good prognosis comprised patients with normal CA 125 before first and second CT courses and patients with elevated baseline CA 125 decreasing by >50% during the first CT course and falling in normal range before the second CT course. Our results indicate that CA 125 variations before the second CT course enable to differentiate responder and nonresponder patients. Furthermore, analysis of the initial changes in CA 125 concentration is not hampered by paradoxical CA 125 increase during the first 14 days after initiation of CT, since it is rarely encountered [3] .
The results presented were not affected by the use of three different techniques for CA 125 determination (all were on the basis of the same antibody) [2] .
Two biases might interfere in the interpretation of our data. First, the CA 125 fall can be partially influenced by a durable effect of surgical debulking. Our CA 125-based criteria, however, remained highly significant in multivariate survival Log-rank test P < 0.0001
analysis which included residual disease as a marker for the effect of surgical tumour reduction. Secondly, in spite of a good response, patients with an initial low CA 125 will have a low CA 125 fall and might be classified in the same group as patients with an elevated baseline CA 125 and a low response. Aware of this situation, we overcame this problem by a separate analysis of patients with high or low baseline CA 125. A similar prognosis was found for patients with a low baseline CA 125 and for those with elevated baseline CA 125 which decreased by >50% during the first CT course. We hypothesise that a good initial response to CT might compensate the deleterious effects on prognosis of a large residual tumour load after surgery, responsible for an elevated CA 125 concentration. This observation, associated with the known heterogeneity of CA 125 production by individual tumours, might partially explain the weak prognostic value of post-surgical CA 125 concentration when considered as single variable [4] [5] [6] [7] [8] [9] [10] [11] [12] . While it is commonly accepted that changes in serum CA 125 during early CT are strong predictors of patient clinical outcome [4, 10] , the prognostic value of absolute CA 125 concentration is still debated. In our study, CA 125 level after one course of CT was found to bear an independent prognostic value, in agreement with the findings of Fisken et al. [10] in multivariate analysis. However, in contrast to a majority of studies [5, [7] [8] [9] [11] [12] [13] [14] , we found that CA 125 after two CT courses had no independent prognostic value for OS.
conclusion
To conclude, our data showed that early CA 125 change induced by the first CT courses was strongly correlated both with the probability of achieving a pCR after CT and with survival duration. Analysis of CA 125 changes before second CT course enables the detection of a subset of patients with poor prognosis for whom an alternative 'non-cross resistant' CT strategy can be tried.
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